The second of a two-part perspective examining why clinical trial enrollment and representation outcomes are shaped long before the first patient is screened.
|Articles|March 3, 2023
Jumo Health Expands Health Equity Service Line
Advertisement
Jumo Health announced that, together with the I Choose Life Foundation (ICLF), it has expanded its health equity service line to include the recruitment and retention of people of color in clinical trials.
To guide their pharmaceutical and biotech customers as they endeavor to develop culturally responsible medications, Jumo Health and ICLF have amassed a national network of more than 2,000 churches that primarily serve Black congregations. Those 2,000 churches, which are located across the United States, have more than 500,000 members.
"Jumo Health explains difficult medical concepts in ways people can understand and act upon," stated Kevin Aniskovich, president and CEO of Jumo Health. "With a keen understanding of health literacy, how various communities consume information, and the importance of storytelling, we ensure that people can 'see themselves' in the information provided; critically important when serving communities that have been historically overlooked by government and industry," continued Aniskovich.
Reference
Jumo Health Launches Suite of Services to Drive Health Equity in Clinical Trials. (2023, March 1). Cision PR Newswire.
Advertisement
Related to this article
Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
2
Bipartisan Bill Would Build Reusable Clinical Trial Networks, With a Focus on Rare Disease
3
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
4
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
5